Literature DB >> 27885422

CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma.

Elena Sanmartín1, Fernando Ortiz-Martínez2, Eloy Pomares-Navarro2, Araceli García-Martínez2, Montserrat Rodrigo-Baños2, Marta García-Escolano2, Leire Andrés3, Enrique Lerma4, Francisco I Aranda5, Pascual Martínez-Peinado6, José M Sempere-Ortells6, Gloria Peiró2,5.   

Abstract

We studied the relationship between CD44 and Forkhead box P3 (FOXP3) gene expression in cell lines and breast carcinomas and their association with clinicopathological variables and patient outcome. We assessed messenger RNA (mRNA) expression of CD44 and FOXP3 by quantitative real-time PCR and determined the number of FOXP3+ Tregs by immunohistochemistry in 264 breast cancer specimens. CD44 was stimulated with hyaluronan treatment, and the accompanying changes in FOXP3 mRNA expression in breast cancer cell lines representing breast cancer subtype were assessed. We found that lower CD44 expression correlated with the presence of necrosis, lymph-vascular invasion, grade 3 tumors, and aggressive phenotype (HER2 and basal-like). FOXP3 mRNA correlated positively with CD44 mRNA expression and Treg content. Moreover, stimulation of CD44 expression by hyaluronan in cell lines increased FOXP3 expression, which supports that their regulation is associated. Survival analysis revealed that low CD44 expression is associated with higher frequency of recurrence. Our findings indicate that CD44 has a regulatory role in FOXP3 expression and is associated with good prognostic factors in breast cancer.

Entities:  

Keywords:  Breast carcinoma; CD44; FOXP3; Prognosis; mRNA expression

Mesh:

Substances:

Year:  2016        PMID: 27885422     DOI: 10.1007/s00428-016-2045-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  44 in total

Review 1.  Understanding the dual nature of CD44 in breast cancer progression.

Authors:  Jeanne M V Louderbough; Joyce A Schroeder
Journal:  Mol Cancer Res       Date:  2011-10-04       Impact factor: 5.852

2.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

4.  FOXP3 suppresses breast cancer metastasis through downregulation of CD44.

Authors:  Cun Zhang; Yujin Xu; Qiang Hao; Shuning Wang; Hong Li; Jialin Li; Yuan Gao; Meng Li; Weina Li; Xiaochang Xue; Shouzhen Wu; Yingqi Zhang; Wei Zhang
Journal:  Int J Cancer       Date:  2015-02-25       Impact factor: 7.396

5.  Prognostic value of CD44 variant expression in primary breast cancer.

Authors:  J A Foekens; P Dall; J G Klijn; P Skroch-Angel; C J Claassen; M P Look; H Ponta; W L Van Putten; P Herrlich; S C Henzen-Logmans
Journal:  Int J Cancer       Date:  1999-06-21       Impact factor: 7.396

6.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.

Authors:  Sebastian Hinz; Laia Pagerols-Raluy; Hans-Heinrich Oberg; Ole Ammerpohl; Sandra Grüssel; Bence Sipos; Robert Grützmann; Christian Pilarsky; Hendrik Ungefroren; Hans-Detlev Saeger; Günter Klöppel; Dieter Kabelitz; Holger Kalthoff
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

7.  FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.

Authors:  Tao Zuo; Runhua Liu; Huiming Zhang; Xing Chang; Yan Liu; Lizhong Wang; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Gains and losses of CD44 expression during breast carcinogenesis and tumour progression.

Authors:  A Bànkfalvi; H J Terpe; D Breukelmann; B Bier; D Rempe; G Pschadka; R Krech; W Böcker
Journal:  Histopathology       Date:  1998-08       Impact factor: 5.087

Review 9.  CD44 Acts as a Signaling Platform Controlling Tumor Progression and Metastasis.

Authors:  Véronique Orian-Rousseau
Journal:  Front Immunol       Date:  2015-04-08       Impact factor: 7.561

10.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Authors:  H R Ali; E Provenzano; S-J Dawson; F M Blows; B Liu; M Shah; H M Earl; C J Poole; L Hiller; J A Dunn; S J Bowden; C Twelves; J M S Bartlett; S M A Mahmoud; E Rakha; I O Ellis; S Liu; D Gao; T O Nielsen; P D P Pharoah; C Caldas
Journal:  Ann Oncol       Date:  2014-06-09       Impact factor: 32.976

View more
  2 in total

1.  Effect of CD44st and HER2 expression on the postoperative prognosis of breast cancer patients.

Authors:  Dan Dan Chen; Jun An Ji; Hai Cui Yan; Guan Hong Huang; Xin Jian Fang
Journal:  Onco Targets Ther       Date:  2019-01-15       Impact factor: 4.147

Review 2.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.